EUVIMEDEUVIMED entdecken
Crossref

Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart

Züleyha Doğanyiğit iD, Aslı Okan, Serpil Taheri, Zeynep Yılmaz, Enes Akyüz, Necdet Demir

Chemical Biology & Drug Design · 2023-11 · 102 (5) · 1085-1096

DOI: 10.1111/cbdd.14308 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 02.08.2023. Verfasst von Züleyha Doğanyiğit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Histology and Embryology, Yozgat Bozok University, Yozgat, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Bozok Üniversitesi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study is to reveal the effects of the use of linagliptin, a DPP‐4 inhibitor due to its beneficial cardiovascular effects, on endoplasmic reticulum stress (ERS) signaling, which is involved in the pathogenesis of cardiovascular complications related to type 1 diabetes. BALB/c female mice ( n = 72) were divided into six groups: control, diabetes+insulin, diabetes+linagliptin, diabetes+linagliptin+insulin, diabetes+TUDCA, and diabetes+TUDCA+insulin. Immunohistochemistry and western blot method, qRT‐PCR, ELISA method, and malondialdehyde (MDA) measurements were performed. Linagliptin administered to the type 1 diabetic mouse heart significantly reduced the expression levels of the total and cleaved forms of ATF6, ATF4, and p‐JNK, caspase 3. Immunohistochemical and western blot analyses revealed that cleaved caspase 3 protein expression was significantly increased in the diabetes+insulin group compared to the other groups. According to ELISA findings, TUDCA was more effective in reducing NOX 1 and MDA levels than linagliptin. While linagliptin decreased the Chop mRNA level, no change was observed in the Grp78 mRNA level. Our findings showed that there was not much difference between the administration of linagliptin alone or in combination with insulin. Our study reveals that linagliptin is an effective therapeutic agent on ERS and apoptotic UPR in type 1 diabetic hearts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Dipeptidyl-Peptidase IV InhibitorsMiceAnimalsFemaleLinagliptinInsulinCaspase 3Unfolded Protein ResponseRNA, MessengerTaurochenodeoxycholic Acid

Stichwörter der Autor:innen

DPP-4 inhibitorlinagliptinmousetype 1 diabetes mellitusunfolded protein response

Substanzen

LinagliptinInsulinCaspase 3Dipeptidyl-Peptidase IV InhibitorsRNA, MessengerursodoxicoltaurineTaurochenodeoxycholic Acid

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Histology and Embryology, Yozgat Bozok University, Yozgat, Turkey.
  • Faculty of Medicine, Department of Medical Biology, Erciyes University, Kayseri, Turkey.
  • Faculty of International Medicine, Department of Biophysics, University of Health Sciences, Istanbul, Turkey.
  • Faculty of Medicine, Department of Histology and Embryology, Akdeniz University, Antalya, Turkey.

ORCID-Profile: Züleyha Doğanyiğit

Förderung

  • Bozok Üniversitesi

Zitieren

APA

Doğanyiğit, Z., Okan, A., Taheri, S., Yılmaz, Z., Akyüz, E., & Demir, N. (2023). Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart. Chemical Biology & Drug Design, 102(5), 1085-1096. https://doi.org/10.1111/cbdd.14308

Vancouver

Doğanyiğit Z, Okan A, Taheri S, Yılmaz Z, Akyüz E, Demir N. Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart. Chemical Biology & Drug Design. 2023;102(5):1085-1096. doi:10.1111/cbdd.14308

BibTeX
@article{Doanyiit2023,
  author = {Doğanyiğit, Züleyha and Okan, Aslı and Taheri, Serpil and Yılmaz, Zeynep and Akyüz, Enes and Demir, Necdet},
  title = {Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  volume = {102},
  number = {5},
  pages = {1085--1096},
  doi = {10.1111/cbdd.14308}
}
Kostenlos starten →